Clinical Trial Update: T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on T lymphocytes engineered to express iCASP9 and ΔCD19 for allogeneic hematopoietic transplantation; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancies

Drugs mentioned

• iCASP9-ΔCD19 T cells

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Graft Versus Host Disease, Hematological Malignancies | Phase 1, Phase 2 | Status: TERMINATED